[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
May 1973

Clinical Pharmacology of Tobramycin in Newborns

Author Affiliations

From the Department of Pediatrics, University of Texas Southwestern Medical School, Dallas.

Am J Dis Child. 1973;125(5):656-660. doi:10.1001/archpedi.1973.04160050012003

Tobramycin is a new aminoglycoside antibiotic with activity against a wide range of bacteria. More than 90% of coliform organisms and Pseudomonas were susceptible in vitro to 5μg/ml of tobramycin. Pharmacokinetic properties of tobramycin in neonates are similar to those of gentamicin. Peak levels of 4μg to 6μg/ml are achieved in serum after a dose of 2.0 mg/kg; it can be given every 12 hours for up to ten days without accumulation. Serum half-life values were inversely related to birth weights and creatinine clearances. It is suggested that tobramycin be used only for the treatment of neonatal infections caused by tobramycin-susceptible gram-negative organisms resistant to both kanamycin and gentamicin. Studies of clinical efficacy and toxicity in neonates are necessary before the drug can be recommended for routine use.